Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Effects of Dual-Task Training on Upper Extremity Function in Parkinson's Disease

NCT07536542 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-04-24
Last updated
2026-06-02

Condition(s) studied

Parkinson Disease (PD)

Investigational drug(s) / intervention(s)

Dual-Task Training

Dual-Task Training: Dual-task training will be applied 3 times per week for 8 weeks, with each session lasting 60 minutes. The program combines motor tasks (such as peg placement, object manipulation, bilateral coordination, and mobility tasks) with simultaneous cognitive tasks (such as backward counting, category-based word generation, and memory tasks).

Study summary

The goal of this clinical trial is to investigate the effects of dual-task training on upper extremity function and muscle thickness in individuals with Parkinson's disease. The main questions it aims to answer are:

Does dual-task training improve upper extremity function in individuals with Parkinson's disease? Does dual-task training lead to changes in upper extremity muscle thickness measured by ultrasonography?

Researchers will compare a dual-task training group with a control group receiving routine care to determine whether 8 weeks of dual-task training results in greater improvements in upper extremity outco

Participants will:

complete baseline and post-intervention assessments of upper extremity function, muscle thickness, grip strength, and pinch strength be assigned to either a control group or a dual-task training group receive dual-task training 3 days per week for 8 weeks if assigned to the intervention group

Eligibility

Sex
ALL
Min age
40 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of idiopathic Parkinson's disease confirmed by a neurologist * Modified Hoehn and Yahr stage 2 to 3 * No medication or dosage change within the last 6 months * Cognitive capacity sufficient to understand and follow instructions, defined as Montreal Cognitive Assessment score ≥21 * Voluntary participation with written informed consent Exclusion Criteria: * Atypical or secondary parkinsonism * Advanced orthopedic condition affecting the upper extremity * Surgery, trauma, or immobilization involving the upper extremity within the last 6 months * Wound or dermatological condition preventing upper extremity ultrasonographic evaluation * Severe visual or hearing loss * Severe depression, psychosis, or communication difficulty * Any additional health problem preventing regular participation in the study

Primary outcome measure(s)

  • Upper Extremity Function — Baseline and 8 weeks
    Upper extremity function will be assessed using the Purdue Pegboard Test. Performance will be recorded as the number of pins placed within the specified time for dominant hand, nondominant hand, and both hands; higher scores indicate better fine motor performance and manual dexterity.
  • Upper Extremity Muscle Thickness — Baseline and 8 weeks
    Muscle thickness of the deltoid, biceps brachii, triceps brachii, and forearm flexor muscles will be measured using ultrasonography. The mean of three repeated measurements for each site will be recorded in millimeters.
  • Hand Grip Strength — Baseline and 8 weeks
    Hand grip strength will be measured using a Jamar hydraulic hand dynamometer according to the ASHT protocol. The mean of three trials will be recorded.
  • Pinch Strength — Baseline and 8 weeks
    Lateral pinch, three-jaw chuck pinch, and two-point pinch strength will be assessed using a pinch meter. The mean of three trials will be recorded in kilograms or Newtons.

Trial sites (1)

FacilityCityRegionStatus
Hacettepe University Ankara Turkey (Türkiye) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07536542 on ClinicalTrials.gov ↗ ← All trials in Turkey